/news

Market Mover: Atyr Pharma (LIFE) Gains at Midday June 23

Equities Staff  |

Shares of Atyr Pharma Inc (NASDAQ: LIFE) are up 5.00% Thursday.

As of 12:01:45 est, Atyr Pharma is currently sitting at $2.84 and has climbed $0.135 per share in trading so far.

Atyr Pharma has moved 9.40% over the last 30 days and has a YTD change of 63.86% based on the most recent close.

The company is set to release earnings on 2022-08-10.

For technical charts, analysis, and more on Atyr Pharma visit the company profile.

About Atyr Pharma Inc

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

To get more information on Atyr Pharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Atyr Pharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Will Mining Stocks Fall Further?
3 Reasons To Be Optimistic About the Global Shipping Industry
The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks



Market Movers

Sponsored Financial Content